Pharmacyte Biotech Inc (PMCB)

$0.80 -0.15 (-15.38%)
Market Cap 8.72M
Revenue (ttm) 0.00
Net Income (ttm) 30.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 478,250
Avg Vol 191,286
Day's Range N/A - N/A
Shares Out 10.74M
Stochastic %K 94%
Beta 0.46
Analysts Strong Buy
Price Target N/A

Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other soli...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 595 2850
Fax: 917 595 2851
Address:
3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States
topstockalerts
topstockalerts May. 15 at 12:17 AM
$PMCB price just keeps finding a way higher
0 · Reply
JH2500
JH2500 May. 14 at 5:03 PM
$PMCB : Will end day well over $.1.30
0 · Reply
ACInvestorBlog
ACInvestorBlog May. 14 at 4:44 PM
$PMCB getting found volume 9x daily avg. If it breaks $1 everything is possible. With $QCLS running it should be trading abv $2
0 · Reply
vcaelum
vcaelum May. 14 at 4:43 PM
$PMCB loading big 0.95 for 1.1 break, but tight SL 0.85. seems penny to dollar land is easy this couple days theme
0 · Reply
buttercup1007
buttercup1007 May. 14 at 4:42 PM
$PMCB can.we break .94?
0 · Reply
luminouslumens
luminouslumens May. 14 at 4:17 PM
$QCLS $PMCB
0 · Reply
Natslover
Natslover May. 13 at 4:40 PM
$PMCB Looks like this is ride or dying with $QCLS. They tend to rise and fall as a team which is what you’d suspect would happen. Hopefully there’s some substance behind what appears, so far, to be speculation.
0 · Reply
green_going_up
green_going_up May. 13 at 4:37 AM
$QCLS $PMCB using Lightsolver technology, developing the first light-based computing system to blockchain! Fyi, Lightsolver recently partnered with Boeing. And, the use of the Lightsolver technology is for crypto and blockchains. Just an fyi, nearly anything and everything transactional that requires settlement and / or verification is blockchainable. All the computations that Lightsolver can solve, across any industry, can be put on a blockchain.
0 · Reply
Natslover
Natslover May. 12 at 4:29 PM
$QCLS I’m wondering if someone knows something because $PMCB also has unusually high volume today. We have seen this before though - just interesting it’s happening on a down day in the market
0 · Reply
ACInvestorBlog
ACInvestorBlog May. 12 at 3:40 PM
$PMCB breakout watch over 80c next pivot lies at 1.2 (Cash rich company Net Cash/Sh:1.74 )
1 · Reply
Latest News on PMCB
Largest borrow rate increases among liquid names

2025-12-31T13:45:13.000Z - 4 months ago

Largest borrow rate increases among liquid names

BTQ CIFR FJET GRRR IRE KDK SLS

Largest borrow rate increases among liquid names

2025-12-30T13:45:15.000Z - 4 months ago

Largest borrow rate increases among liquid names

BILI BTQ LUNR ORBS OTLK SVXY TLPH

Largest borrow rate increases among liquid names

2025-12-15T13:45:16.000Z - 5 months ago

Largest borrow rate increases among liquid names

DUST ITUB MSOS NNE STM XME

PharmaCyte sells Femasys stake, sees cash position rising to $20M

2025-11-25T14:25:20.000Z - 6 months ago

PharmaCyte sells Femasys stake, sees cash position rising to $20M

FEMY

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 6 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

FEMY

PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M

2025-09-02T13:30:08.000Z - 9 months ago

PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Sep 2, 2025, 9:20 AM EDT - 9 months ago

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

Aug 20, 2025, 9:15 AM EDT - 9 months ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

Aug 18, 2025, 9:15 AM EDT - 9 months ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech

2024-05-21T13:14:03.000Z - 2 years ago

MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 2 years ago

MyMD Pharmaceuticals Secures Strategic Investments

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024, 9:00 AM EDT - 2 years ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position

2023-11-15T13:37:10.000Z - 2 years ago

PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position

FEMY

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

Nov 15, 2023, 8:30 AM EST - 2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

Femasys announces upfront investment of $6.85M by PharmaCyte

2023-11-15T12:37:56.000Z - 2 years ago

Femasys announces upfront investment of $6.85M by PharmaCyte

FEMY

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Oct 31, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

PharmaCyte Biotech Announces Final Results of Tender Offer

Jun 15, 2023, 9:15 AM EDT - 3 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

PharmaCyte Biotech announces second $10M share repurchase plan

2023-02-02T14:15:52.000Z - 3 years ago

PharmaCyte Biotech announces second $10M share repurchase plan

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Feb 2, 2023, 9:00 AM EST - 3 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Oct 7, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Aug 15, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 12:49 PM EDT - 4 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 28, 2022, 9:00 AM EDT - 4 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 21, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 19, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 11, 2022, 6:00 AM EDT - 4 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 4 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jul 5, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 23, 2022, 9:00 AM EDT - 4 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 15, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 13, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 9, 2022, 9:00 AM EDT - 4 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 8, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

Jun 2, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 23, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

May 11, 2022, 9:00 AM EDT - 4 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 27, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 19, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 13, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Apr 5, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 22, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Mar 16, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 22, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Feb 14, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 6, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Jan 4, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 28, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 15, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Dec 8, 2021, 10:16 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 30, 2021, 1:05 AM EST - 4 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Nov 12, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 27, 2021, 9:00 AM EDT - 5 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 21, 2021, 9:00 AM EDT - 5 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 16, 2021, 9:00 AM EDT - 5 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Sep 8, 2021, 9:00 AM EDT - 5 years ago

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

Aug 31, 2021, 9:20 AM EDT - 5 years ago

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

Aug 25, 2021, 9:00 AM EDT - 5 years ago

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

topstockalerts
topstockalerts May. 15 at 12:17 AM
$PMCB price just keeps finding a way higher
0 · Reply
JH2500
JH2500 May. 14 at 5:03 PM
$PMCB : Will end day well over $.1.30
0 · Reply
ACInvestorBlog
ACInvestorBlog May. 14 at 4:44 PM
$PMCB getting found volume 9x daily avg. If it breaks $1 everything is possible. With $QCLS running it should be trading abv $2
0 · Reply
vcaelum
vcaelum May. 14 at 4:43 PM
$PMCB loading big 0.95 for 1.1 break, but tight SL 0.85. seems penny to dollar land is easy this couple days theme
0 · Reply
buttercup1007
buttercup1007 May. 14 at 4:42 PM
$PMCB can.we break .94?
0 · Reply
luminouslumens
luminouslumens May. 14 at 4:17 PM
$QCLS $PMCB
0 · Reply
Natslover
Natslover May. 13 at 4:40 PM
$PMCB Looks like this is ride or dying with $QCLS. They tend to rise and fall as a team which is what you’d suspect would happen. Hopefully there’s some substance behind what appears, so far, to be speculation.
0 · Reply
green_going_up
green_going_up May. 13 at 4:37 AM
$QCLS $PMCB using Lightsolver technology, developing the first light-based computing system to blockchain! Fyi, Lightsolver recently partnered with Boeing. And, the use of the Lightsolver technology is for crypto and blockchains. Just an fyi, nearly anything and everything transactional that requires settlement and / or verification is blockchainable. All the computations that Lightsolver can solve, across any industry, can be put on a blockchain.
0 · Reply
Natslover
Natslover May. 12 at 4:29 PM
$QCLS I’m wondering if someone knows something because $PMCB also has unusually high volume today. We have seen this before though - just interesting it’s happening on a down day in the market
0 · Reply
ACInvestorBlog
ACInvestorBlog May. 12 at 3:40 PM
$PMCB breakout watch over 80c next pivot lies at 1.2 (Cash rich company Net Cash/Sh:1.74 )
1 · Reply
SuperGreenToday
SuperGreenToday May. 5 at 9:15 PM
$PMCB Share Price: $0.74 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.13 – $0.16 Potential Upside: 58% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
jboy92860
jboy92860 May. 4 at 1:56 AM
$PMCB I have owned this for over 10 years with FDA promises and splits that have destroyed my investment…..This is complete garbage.
1 · Reply
Value_Trader_777
Value_Trader_777 Apr. 22 at 6:07 PM
$PMCB should be getting an update on their meeting with the FDA by mid May the latest… then if the FDA fully lifts the hold on their Pancreatic Cancer trial expect a moonshot
1 · Reply
luminouslumens
luminouslumens Apr. 15 at 7:48 PM
$QCLS $PMCB with quantum + semis ripping, bout time for another run, no? 🧐
0 · Reply
KingChad
KingChad Apr. 15 at 3:56 PM
$PMCB Glad I bought in. This could chase to $1 or more.
0 · Reply
KingChad
KingChad Apr. 14 at 7:21 PM
$PMCB could pop if it gets some volume. I like it.
0 · Reply
Natslover
Natslover Apr. 14 at 2:36 PM
$PMCB Is it riding with $QCLS? Interesting early volume here
0 · Reply
slick3333
slick3333 Apr. 9 at 1:12 AM
$PMCB when split date?
1 · Reply
_RG1_
_RG1_ Apr. 7 at 7:26 PM
$PMCB Just a matter of time for a boom up or down let’s hope is up
0 · Reply
paulengman
paulengman Apr. 6 at 12:23 AM
$PMCB Why did my Dad buy this stock for me 10 years ago? He acted like they had a cure for cancer or something...what a loser.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:45 PM
$PMCB annual meeting approved a reverse split authorization and added 2 million shares to the 2022 equity plan pool.
0 · Reply
matans844
matans844 Mar. 30 at 6:57 PM
$PMCB $QCLS LOL INFINITY!!
0 · Reply